Skip to content

CorMedix CRMD Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Merck & Co. logo
Merck & Co.MRK
$157M+726%
Merit Medical Systems logo
Merit Medical SystemsMMSI
$2.78M-78.9%
Emergent Biosolutions logo
Emergent BiosolutionsEBS
$400K
Abbott logo
AbbottABT
$116M-59.6%
ICU Medical logo
ICU MedicalICUI
$0-100%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
$10.13M+59.3%

Other financials

Income statement

See full
Revenue$127.4M+226%
Gross profit$115.4M+207%
Operating income$63.7M+216%
Net income$38.6M+87.0%
EPS (diluted)$0.43+43.3%

Balance sheet

See full
Cash & equivalents$179.1M+170%
Total debt$4.3M+729%
Total equity$437.0M+280%
Total assets$815.6M+445%

Cash flow

See full
Operating cash flow$42.4M+115%
CapEx$729.0K+7,190%
Free cash flow$41.7M+111%

Valuation

See full
Market cap$605.65M-34.4%
P/E3.4×
P/S1.5×-9.6×

Profitability

See full
Gross margin91.9%-3.5pp
Operating margin48.4%
Net margin45.2%
FCF margin48.7%+38.8pp

Returns & leverage

See full
Return on equity65.6%
Debt / equity0.0×
Current ratio-1.2×

Where this comes from

Reported directly by CorMedix in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.

The official record: CorMedix’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about CorMedix's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CorMedix's stock issuance proceeds?
CorMedix (CRMD) reported stock issuance proceeds of $0 in Q1 2026.
How has CorMedix's stock issuance proceeds changed year-over-year?
CorMedix's stock issuance proceeds decreased by 100.0% year-over-year, from $6.76M to $0.
What does stock issuance proceeds mean?
Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.